Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Clonal haematopoiesis as a risk factor for therapy-related myeloid neoplasms in patients with chronic lymphocytic leukaemia treated with chemo-(immuno)therapy

MT. Voso, T. Pandzic, G. Falconi, M. Denčić-Fekete, E. De Bellis, L. Scarfo, V. Ljungström, M. Iskas, G. Del Poeta, P. Ranghetti, S. Laidou, A. Cristiano, K. Plevova, S. Imbergamo, M. Engvall, A. Zucchetto, C. Salvetti, FR. Mauro, N....

. 2022 ; 198 (1) : 103-113. [pub] 20220311

Jazyk angličtina Země Velká Británie

Typ dokumentu časopisecké články, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc22017858

Clonal haematopoiesis of indeterminate potential (CHIP) may predispose for the development of therapy-related myeloid neoplasms (t-MN). Using target next-generation sequencing (t-NGS) panels and digital droplet polymerase chain reactions (ddPCR), we studied the myeloid gene mutation profiles of patients with chronic lymphocytic leukaemia (CLL) who developed a t-MN after treatment with chemo-(immuno)therapy. Using NGS, we detected a total of 30 pathogenic/likely pathogenic (P/LP) variants in 10 of 13 patients with a t-MN (77%, median number of variants for patient: 2, range 0-6). The prevalence of CHIP was then backtracked in paired samples taken at CLL diagnosis in eight of these patients. Six of them carried at least one CHIP-variant at the time of t-MN (median: 2, range: 1-5), and the same variants were present in the CLL sample in five cases. CHIP variants were present in 34 of 285 patients from a population-based CLL cohort, which translates into a significantly higher prevalence of CHIP in patients with a CLL who developed a t-MN, compared to the population-based cohort (5/8, 62.5% vs. 34/285, 12%, p = 0.0001). Our data show that CHIP may be considered as a novel parameter affecting treatment algorithms in patients with CLL, and highlight the potential of using chemo-free therapies in CHIP-positive cases.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc22017858
003      
CZ-PrNML
005      
20220804134427.0
007      
ta
008      
220720s2022 xxk f 000 0|eng||
009      
AR
024    7_
$a 10.1111/bjh.18129 $2 doi
035    __
$a (PubMed)35277855
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxk
100    1_
$a Voso, Maria-Teresa $u Department of Biomedicine and Prevention, University of Tor Vergata, Rome, Italy $1 https://orcid.org/0000000261644761
245    10
$a Clonal haematopoiesis as a risk factor for therapy-related myeloid neoplasms in patients with chronic lymphocytic leukaemia treated with chemo-(immuno)therapy / $c MT. Voso, T. Pandzic, G. Falconi, M. Denčić-Fekete, E. De Bellis, L. Scarfo, V. Ljungström, M. Iskas, G. Del Poeta, P. Ranghetti, S. Laidou, A. Cristiano, K. Plevova, S. Imbergamo, M. Engvall, A. Zucchetto, C. Salvetti, FR. Mauro, N. Stavroyianni, L. Cavelier, P. Ghia, K. Stamatopoulos, E. Fabiani, P. Baliakas
520    9_
$a Clonal haematopoiesis of indeterminate potential (CHIP) may predispose for the development of therapy-related myeloid neoplasms (t-MN). Using target next-generation sequencing (t-NGS) panels and digital droplet polymerase chain reactions (ddPCR), we studied the myeloid gene mutation profiles of patients with chronic lymphocytic leukaemia (CLL) who developed a t-MN after treatment with chemo-(immuno)therapy. Using NGS, we detected a total of 30 pathogenic/likely pathogenic (P/LP) variants in 10 of 13 patients with a t-MN (77%, median number of variants for patient: 2, range 0-6). The prevalence of CHIP was then backtracked in paired samples taken at CLL diagnosis in eight of these patients. Six of them carried at least one CHIP-variant at the time of t-MN (median: 2, range: 1-5), and the same variants were present in the CLL sample in five cases. CHIP variants were present in 34 of 285 patients from a population-based CLL cohort, which translates into a significantly higher prevalence of CHIP in patients with a CLL who developed a t-MN, compared to the population-based cohort (5/8, 62.5% vs. 34/285, 12%, p = 0.0001). Our data show that CHIP may be considered as a novel parameter affecting treatment algorithms in patients with CLL, and highlight the potential of using chemo-free therapies in CHIP-positive cases.
650    _2
$a protokoly protinádorové kombinované chemoterapie $x škodlivé účinky $7 D000971
650    _2
$a klonální hematopoéza $x genetika $7 D000082182
650    _2
$a lidé $7 D006801
650    12
$a chronická lymfatická leukemie $x farmakoterapie $x genetika $x patologie $7 D015451
650    _2
$a mutace $7 D009154
650    12
$a sekundární malignity $x etiologie $x genetika $7 D016609
650    _2
$a rizikové faktory $7 D012307
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Pandzic, Tatjana $u Department of Immunology, Genetics and Pathology, Science for Life Laboratory, Uppsala University, Uppsala, Sweden $u Department of Clinical Genetics, Uppsala University Hospital, Uppsala, Sweden
700    1_
$a Falconi, Giulia $u Department of Biomedicine and Prevention, University of Tor Vergata, Rome, Italy $1 https://orcid.org/0000000176991427
700    1_
$a Denčić-Fekete, Marija $u Clinic for Hematology, Clinical Center of Serbia, Belgrade, Serbia
700    1_
$a De Bellis, Eleonora $u Department of Biomedicine and Prevention, University of Tor Vergata, Rome, Italy
700    1_
$a Scarfo, Lydia $u Strategic Research Programme in CLL, Division of Experimental Oncology, IRCCS Ospedale San Raffaele and Università Vita-Salute San Raffaele, Milan, Italy
700    1_
$a Ljungström, Viktor $u Department of Immunology, Genetics and Pathology, Science for Life Laboratory, Uppsala University, Uppsala, Sweden $u Department of Clinical Genetics, Uppsala University Hospital, Uppsala, Sweden
700    1_
$a Iskas, Michail $u Hematology Department and HCT Unit, G. Papanicolaou Hospital, Thessaloniki, Greece
700    1_
$a Del Poeta, Giovanni $u Department of Biomedicine and Prevention, University of Tor Vergata, Rome, Italy
700    1_
$a Ranghetti, Pamela $u Strategic Research Programme in CLL, Division of Experimental Oncology, IRCCS Ospedale San Raffaele and Università Vita-Salute San Raffaele, Milan, Italy
700    1_
$a Laidou, Stamatia $u Institute of Applied Biosciences, Center for Research and Technology Hellas, Thessaloniki, Greece
700    1_
$a Cristiano, Antonio $u Department of Biomedicine and Prevention, University of Tor Vergata, Rome, Italy $1 https://orcid.org/0000000170558577
700    1_
$a Plevova, Karla $u Institute of Medical Genetics and Genomics, Faculty of Medicine, Masaryk University, Brno, Czech Republic $u Department of Internal Medicine - Haematology and Oncology, University Hospital Brno, Brno, Czech Republic
700    1_
$a Imbergamo, Silvia $u Hematology and Clinical Immunology, Department of Hematology, Hospital of Padua, Padua, Italy
700    1_
$a Engvall, Marie $u Department of Immunology, Genetics and Pathology, Science for Life Laboratory, Uppsala University, Uppsala, Sweden $u Department of Clinical Genetics, Uppsala University Hospital, Uppsala, Sweden
700    1_
$a Zucchetto, Antonella $u Clinical and Experimental Onco-Hematology Unit, Centro di Riferimento Oncologico di Aviano (CRO), IRCCS, Aviano, Italy
700    1_
$a Salvetti, Chiara $u Division of Hematology, University of Turin, Turin, Italy
700    1_
$a Mauro, Francesca R $u Department of Translational and Precision Medicine, Hematology, 'Sapienza' University, Rome, Italy $1 https://orcid.org/0000000324259474
700    1_
$a Stavroyianni, Niki $u Hematology Department and HCT Unit, G. Papanicolaou Hospital, Thessaloniki, Greece
700    1_
$a Cavelier, Lucia $u Department of Immunology, Genetics and Pathology, Science for Life Laboratory, Uppsala University, Uppsala, Sweden $u Department of Clinical Genetics, Uppsala University Hospital, Uppsala, Sweden
700    1_
$a Ghia, Paolo $u Strategic Research Programme in CLL, Division of Experimental Oncology, IRCCS Ospedale San Raffaele and Università Vita-Salute San Raffaele, Milan, Italy
700    1_
$a Stamatopoulos, Kostas $u Institute of Applied Biosciences, Center for Research and Technology Hellas, Thessaloniki, Greece $u Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden
700    1_
$a Fabiani, Emiliano $u Department of Biomedicine and Prevention, University of Tor Vergata, Rome, Italy $u UniCamillus-Saint Camillus International University of Health Sciences, Rome, Italy $1 https://orcid.org/0000000262098934
700    1_
$a Baliakas, Panagiotis $u Department of Immunology, Genetics and Pathology, Science for Life Laboratory, Uppsala University, Uppsala, Sweden $u Department of Clinical Genetics, Uppsala University Hospital, Uppsala, Sweden $1 https://orcid.org/0000000256347156
773    0_
$w MED00009374 $t British journal of haematology $x 1365-2141 $g Roč. 198, č. 1 (2022), s. 103-113
856    41
$u https://pubmed.ncbi.nlm.nih.gov/35277855 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20220720 $b ABA008
991    __
$a 20220804134421 $b ABA008
999    __
$a ok $b bmc $g 1821786 $s 1169101
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2022 $b 198 $c 1 $d 103-113 $e 20220311 $i 1365-2141 $m British journal of haematology $n Br J Haematol $x MED00009374
LZP    __
$a Pubmed-20220720

Najít záznam

Citační ukazatele

Pouze přihlášení uživatelé

Možnosti archivace